Form 4: Cytokinetics Director Santo J. Costa Reports Stock Transactions
SEC Form 4 Filing
Director Santo J. Costa reports acquisition and disposal of Cytokinetics Inc. common stock and acquisition of non-qualified stock options.
Summary
- On May 15, 2024, Santo J. Costa, a director of Cytokinetics Inc., reported acquiring 5,600 shares of common stock.
- On the same day, Costa disposed of 20,600 shares of common stock.
- Following these transactions, Costa beneficially owns 20,600 shares of common stock.
- Costa also acquired 3,636 non-qualified stock options with an exercise price of $60.50, exercisable from June 17, 2024, and expiring on May 15, 2034.
- These options relate to 3,636 shares of common stock.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing. The sentiment is neutral as it simply reports transactions.
Industry Context
Form 4 filings are standard disclosures required by the SEC for insiders (directors, officers, and 10% owners) of publicly traded companies, providing transparency into their transactions in the company's stock.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the director's view of the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of stock acquisition, disposal, and option acquisition. |
| 06/17/2024 | Date the non-qualified stock options become exercisable. |
| 05/15/2034 | Expiration date of the non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.